TIDMDEST
RNS Number : 8116M
Destiny Pharma PLC
27 September 2021
Destiny Pharma plc
("Destiny Pharma" or "the Company")
Expansion of clinical pipeline
New XF-73 skin infection clinical programme planned to start in
China led by existing partner, China Medical System Holdings
Limited
Targeting prevention and treatment of superficial skin
infections caused by bacteria
Brighton, United Kingdom - 27 September 2021 - Destiny Pharma
(AIM: DEST), a clinical stage biotechnology company focused on the
development of novel medicines to prevent life threatening
infections, is pleased to announce that the Company's China
regional partner and investor, China Medical System Holdings
Limited (CMS), is establishing a new programme with XF-73 targeting
the prevention and treatment of superficial skin infections caused
by bacteria.
The programme will be run in China and will be focused on
delivering a novel product in the local regulatory environment. The
project will be led, managed and funded by CMS. Destiny Pharma will
contribute scientific advice as required through a steering
committee to the expert dermatology team at CMS. CMS has an
extensive portfolio of dermatology assets and an expert
understanding of the market and its requirements through its
existing sales and marketing infrastructure.
Destiny Pharma has cross-reference rights to data generated from
the programme and, in the future, could start a similar skin
infection clinical programme focused on commercial territories
outside those held by CMS (China and other Asian countries
excluding Japan).
Destiny Pharma is currently running its own dermal programme
with XF-73 in a different indication targeting the prevention and
treatment of serious infections associated with burns and open
wounds. This programme is in collaboration with both the US
government's National Institute of Allergy and Infectious Diseases
(NIAID), and as part of the Global AMR Innovation Fund (GAMRIF)
funded UK-China bilateral partnership to tackle AMR which is
managed by Innovate UK. This new CMS initiative adds a further,
differentiated product to Destiny Pharma's pipeline, leveraging off
the very strong efficacy, formulation and safety package generated
to date by the XF platform.
Neil Clark , Chief Executive Officer of Destiny Pharma said: "We
are very pleased to announce the addition of this new XF-73 dermal
clinical programme to our portfolio with our partner China Medical
System Holdings Limited. We are looking forward to the future
development of this programme as well as our other infection
prevention assets as we continue to build a high quality,
late-stage biotechnology company."
-END-
For further information, please contact:
Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0)1273 704 440
pressoffice@destinypharma.com
Optimum Strategic Communications
Mary Clark / Hollie Vile / Manel Mateus
DestinyPharma@optimumcomms.com
+44 (0) 208 078 4357
finnCap Ltd (Nominated Adviser and Joint Broker)
Geoff Nash / Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0)20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes / Claes Spång / Nigel Birks
+44 (0)20 3705 9321
MC Associates AG
Anne Hennecke / Andreas Burckhardt
+49-211-529252-0
About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology
company focused on the development of novel medicines that can
prevent life-threatening infections. Its pipeline has novel
microbiome-based biotherapeutics and XF drug clinical assets
including NTCD-M3, a Phase 3 ready treatment for the prevention of
C. difficile infection (CDI) recurrence which is the leading cause
of hospital acquired infection in the US and also XF-73 nasal gel,
which has recently completed a positive Phase 2b clinical trial
targeting the prevention of post-surgical staphylococcal hospital
infections including MRSA. It is also co-developing SPOR-COV, a
novel, biotherapeutic product for the prevention of COVID-19 and
other viral respiratory infections and has earlier grant funded XF
research projects.
For further information, please visit https://www.destinypharma.com
Forward looking statements
Certain information contained in this announcement, including
any information as to the Group's strategy, plans or future
financial or operating performance, constitutes "forward-looking
statements". These forward looking statements may be identified by
the use of forward-looking terminology, including the terms
"believes", "estimates", "anticipates", "projects", "expects",
"intends", "aims", "plans", "predicts", "may", "will", "seeks"
"could" "targets" "assumes" "positioned" or "should" or, in each
case, their negative or other variations or comparable terminology,
or by discussions of strategy, plans, objectives, goals, future
events or intentions. These forward-looking statements include all
matters that are not historical facts. They appear in a number of
places throughout this announcement and include statements
regarding the intentions, beliefs or current expectations of the
Directors concerning, among other things, the Group's results of
operations, financial condition, prospects, growth, strategies and
the industries in which the Group operates. The directors of the
company believe that the expectations reflected in these statements
are reasonable, but may be affected by a number of variables which
could cause actual results or trends to differ materially. Each
forward-looking statement speaks only as of the date of the
particular statement. By their nature, forward-looking statements
involve risks and uncertainties because they relate to events and
depend on circumstances that may or may not occur in the future or
are beyond the Group's control. Forward looking statements are not
guarantees of future performance. Even if the Group's actual
results of operations, financial condition and the development of
the industries in which the Group operates are consistent with the
forward-looking statements contained in this document, those
results or developments may not be indicative of results or
developments in subsequent periods.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCPPUBPBUPGGCW
(END) Dow Jones Newswires
September 27, 2021 01:59 ET (05:59 GMT)
Destiny Pharma (LSE:DEST)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Destiny Pharma (LSE:DEST)
Gráfica de Acción Histórica
De May 2023 a May 2024